Annexin Pharmaceuticals AB (publ) (STO:ANNX)
Sweden flag Sweden · Delayed Price · Currency is SEK
13.70
-0.15 (-1.08%)
May 21, 2026, 12:14 PM CET

STO:ANNX Balance Sheet

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
17.0727.416.3421.4231.1149.48
Cash & Short-Term Investments
17.0727.416.3421.4231.1149.48
Cash Growth
-62.26%67.69%-23.71%-31.17%-37.12%172.88%
Other Receivables
0.740.380.422.631.861.02
Receivables
0.740.380.422.631.861.02
Prepaid Expenses
0.630.790.630.870.670.22
Total Current Assets
18.4428.5717.3824.9233.6550.72
Property, Plant & Equipment
1.091.121.081.171.261.35
Long-Term Investments
0.310.310.310.310.410.15
Other Intangible Assets
0.140.160.270.370.470.58
Other Long-Term Assets
----0.89-
Total Assets
19.9830.1619.0426.7636.6852.79
Accounts Payable
2.952.972.964.333.333.51
Accrued Expenses
2.291.931.983.32.431.7
Other Current Liabilities
0.330.330.390.320.770.84
Total Current Liabilities
5.565.225.327.956.536.06
Other Long-Term Liabilities
-0-----
Total Liabilities
5.565.225.327.956.536.06
Common Stock
11.6811.688.825.742.5627.45
Additional Paid-In Capital
386.61386.61341.36299.29269.63220.91
Retained Earnings
-383.87-373.36-336.46-286.21-242.16-201.63
Comprehensive Income & Other
----0.12-
Shareholders' Equity
14.4224.9313.7118.8130.1546.73
Total Liabilities & Equity
19.9830.1619.0426.7636.6852.79
Net Cash (Debt)
17.0727.416.3421.4231.1149.48
Net Cash Growth
-62.26%67.69%-23.71%-31.17%-37.12%172.88%
Net Cash Per Share
-4.143.6112.8221.2760.31
Filing Date Shares Outstanding
-7.065.333.471.541.37
Total Common Shares Outstanding
-7.065.333.471.541.37
Working Capital
12.8723.3412.0616.9727.1244.66
Book Value Per Share
-3.532.575.4319.5234.05
Tangible Book Value
14.2824.7713.4518.4429.6846.15
Tangible Book Value Per Share
-3.512.525.3219.2133.63
Source: S&P Global Market Intelligence. Standard template. Financial Sources.